Agios Pharmaceuticals Stock Forecast NASDAQ:AGIO

Price Target and Analyst Ratings

Most Recent Rating

On July 30, 2021 "SVB Leerink" gave "$50.00" rating for AGIO. The price target was set to $48.090.0%.

Last 30 Days

Historical Ratings

Date	Rating	Action	Authority	Current Price	Target Price
2021-07-30	$50.00	Initiated by	SVB Leerink	$48.09	$48.090.0%
2021-07-30	$88.00 - $93.00	Target Raised by	HC Wainwright	$48.09	$49.84→0.3%
2021-07-30	$58.00 - $39.00	Downgraded by	The Goldman Sachs Group	$48.09	$49.84→0.3%
2021-06-30	Market Perform	Initiated by	Raymond James	$55.11
2021-06-13	Hold	Reiterated by	Oppenheimer	$57.74
2021-06-10	Buy	Initiated by	HC Wainwright	$59.50	$88.00
2021-06-10	Buy	Initiated by	HC Wainwright	$59.50
2021-05-06	Buy	Target Raised by	Canaccord Genuity	$55.10	$57.00 → $65.00
2021-04-30	Positive - Overweight	Target Raised by	Barclays	$55.80	$65.00 → $70.00
2021-04-30	Buy	Target Raised by	Canaccord Genuity	$55.80	$57.00 → $65.00
2021-04-30	Neutral	Initiated by	The Goldman Sachs Group	$55.80
2021-03-08	Overweight - Neutral	Reiterated by	JPMorgan Chase & Co.	$48.31	$54.00
2021-03-04	Outperform - Market Perform	Reiterated by	SVB Leerink	$47.33	$55.00 → $50.00
2021-03-01	Overweight - Neutral	Downgraded by	JPMorgan Chase & Co.	$47.51	$64.00 → $54.00
2021-02-26	Outperform - Market Perform	Downgraded by	SVB Leerink	$47.44	$55.00 → $50.00
2021-02-26	Outperform - Market Perform	Downgraded by	SVB Leerink	$47.44
2021-01-27	Positive - Overweight	Target Raised by	Barclays	$45.84	$58.00 → $65.00
2021-01-27	Outperform	Target Raised by	SVB Leerink	$45.84	$51.00 → $55.00
2021-01-27	Positive - Overweight	Reiterated by	Barclays	$45.84	$58.00 → $65.00
2021-01-14		Target Raised by	Barclays	$45.95	$50.00 → $58.00
2020-12-28	Buy	Target Lowered by	Canaccord Genuity	$44.54	$70.00 → $57.00
2020-12-22		Target Lowered by	SVB Leerink	$41.85	$61.00 → $51.00
2020-12-22		Target Lowered by	Royal Bank of Canada	$41.85	$59.00 → $66.00
2020-12-21		Target Raised by	Piper Sandler	$42.62	$73.00 → $80.00
2020-12-09		Target Lowered by	BMO Capital Markets	$33.80	$57.00 → $50.00
2020-12-09	Outperform	Target Lowered by	SVB Leerink	$33.80	$67.00 → $61.00
2020-11-20	Overweight	Target Raised by	Barclays	$43.59	$46.00 → $50.00
2020-11-19	Overweight	Target Raised by	Cantor Fitzgerald	$41.79	$68.00 → $79.00
2020-10-22	Equal Weight - Overweight	Upgraded by	Barclays	$38.87	$46.00
2020-10-19	Buy	Target Lowered by	Needham & Company LLC	$35.28	$71.00 → $69.00
2020-10-19	Positive - Outperform	Target Lowered by	SVB Leerink	$35.28	$72.00 → $67.00
2020-10-19	Buy	Reiterated by	Canaccord Genuity	$35.28	$70.00
2020-10-19	Overweight	Target Lowered by	Piper Sandler	$35.28	$80.00 → $73.00
2020-07-31	Overweight	Target Raised by	Cantor Fitzgerald	$45.32	$70.00 → $72.00
2020-07-31	Buy	Reiterated by	Canaccord Genuity	$45.32	$72.00
2020-07-30	Buy	Initiated by	Needham & Company LLC	$47.45	$71.00
2020-06-15	Hold	Reiterated by	Oppenheimer	$48.30
2020-06-15	Outperform	Target Raised by	SVB Leerink	$48.30	$70.00 → $72.00
2020-06-15	Buy	Target Raised by	Citigroup	$48.30	$64.00 → $75.00
2020-06-15	Buy	Target Raised by	Guggenheim	$48.30	$60.00 → $66.00
2020-06-12	Overweight	Target Raised by	Piper Sandler	$47.14	$70.00 → $80.00
2020-05-04	Overweight	Target Raised by	JPMorgan Chase & Co.	$38.40	$72.00 → $82.00
2020-05-01	Buy	Reiterated by	Canaccord Genuity	$37.01	$72.00
2020-04-30	Hold	Reiterated by	Oppenheimer	$41.14
2020-04-30	Buy	Reiterated by	Needham & Company LLC	$41.14	$71.00

AGIO Stock Trend

The stock lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $48.05 will firstly indicate a slower falling rate, but may be the first sign of a trend shift.

Given the current short-term trend, the stock is expected to fall -20.30% during the next 3 months and, with a 90% probability hold a price between $29.23 and $38.29 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.

Data

Date	Bottom	Mid	Top
2021-09-30	$36.48	$42.17	$47.85
2021-10-01	$36.29	$41.97	$47.66
2021-10-04	$36.09	$41.78	$47.46
2021-10-05	$35.90	$41.58	$47.27
2021-10-06	$35.70	$41.39	$47.07
2021-10-07	$35.51	$41.20	$46.88
2021-10-08	$35.32	$41.00	$46.69
2021-10-11	$35.12	$40.81	$46.49
2021-10-12	$34.93	$40.61	$46.30
2021-10-13	$34.73	$40.42	$46.10
2021-10-14	$34.54	$40.22	$45.91
2021-10-15	$34.34	$40.03	$45.71
2021-10-18	$34.15	$39.84	$45.52
2021-10-19	$33.96	$39.64	$45.33
2021-10-20	$33.76	$39.45	$45.13
2021-10-21	$33.57	$39.25	$44.94
2021-10-22	$33.37	$39.06	$44.74
2021-10-25	$33.18	$38.86	$44.55
2021-10-26	$32.99	$38.67	$44.36
2021-10-27	$32.79	$38.48	$44.16
2021-10-28	$32.60	$38.28	$43.97
2021-10-29	$32.40	$38.09	$43.77
2021-11-01	$32.21	$37.89	$43.58
2021-11-02	$32.01	$37.70	$43.38
2021-11-03	$31.82	$37.50	$43.19
2021-11-04	$31.63	$37.31	$43.00
2021-11-05	$31.43	$37.12	$42.80
2021-11-08	$31.24	$36.92	$42.61
2021-11-09	$31.04	$36.73	$42.41
2021-11-10	$30.85	$36.53	$42.22

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The companys product candidates include AG-221, an potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II, Phase Ib combination, and Phase III IDHENTIFY clinical trials for the treatment of hematologic maligna... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!